Recruiting
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Relapsed or Refractory Acute Myeloid Leukemia
March 11, 2019
February 2024
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety,
Tolerability, Pharmacokinetics, and Pharmacodynamics of HM43239 in Patients with Relapsed or
Refractory Acute Myeloid Leukemia (AML)
Phase 1/Phase 2
218
February 2024
Interventional
Aptose Biosciences Inc.
The following cities have HM43239 clinical trial sites. Please check back often as locations will be updated.
For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
Contact Us Visit ClinicalTrials.gov
The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.